ABSTRACT
Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS) are two imprinting disorders associated with opposite molecular alterations in the 11p15.5 imprinting centres. Their clinical diagnosis is confirmed by molecular testing in 50-70% of patients. The authors from different reference centres for BWS and SRS have identified single patients with unexpected and even contradictory molecular findings in respect to the clinical diagnosis. These patients clinically do not fit the characteristic phenotypes of SRS or BWS, but illustrate their clinical heterogeneity. Thus, comprehensive molecular testing is essential for accurate diagnosis and appropriate management, to avoid premature clinical diagnosis and anxiety for the families.
Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Silver-Russell Syndrome/genetics , Beckwith-Wiedemann Syndrome/diagnosis , Chromosomes, Human, Pair 11/genetics , DNA Methylation , Genetic Predisposition to Disease/genetics , Genetic Testing , Humans , Phenotype , Silver-Russell Syndrome/diagnosisABSTRACT
BACKGROUND: Imprinting disorders are rare diseases resulting from altered expression of imprinted genes, which exhibit parent-of-origin-specific expression patterns regulated through differential DNA methylation. A subgroup of patients with imprinting disorders have DNA methylation changes at multiple imprinted loci, a condition referred to as multi-locus imprinting disturbance (MLID). MLID is recognised in most but not all imprinting disorders and is also found in individuals with atypical clinical features; the presence of MLID often alters the management or prognosis of the affected person. Some cases of MLID are caused by trans-acting genetic variants, frequently not in the patients but their mothers, which have counselling implications. There is currently no consensus on the definition of MLID, clinical indications prompting testing, molecular procedures and methods for epigenetic and genetic diagnosis, recommendations for laboratory reporting, considerations for counselling, and implications for prognosis and management. The purpose of this study is thus to cover this unmet need. METHODS: A comprehensive literature search was conducted resulting in identification of more than 100 articles which formed the basis of discussions by two working groups focusing on clinical diagnosis (n = 12 members) and molecular testing (n = 19 members). Following eight months of preparations and regular online discussions, the experts from 11 countries compiled the preliminary documentation and determined the questions to be addressed during a face-to-face meeting which was held with the attendance of the experts together with four representatives of patient advocacy organisations. RESULTS: In light of available evidence and expert consensus, we formulated 16 propositions and 8 recommendations as interim guidance for the clinical and molecular diagnosis of MLID. CONCLUSIONS: MLID is a molecular designation, and for patients with MLID and atypical phenotypes, we propose the alternative term multi-locus imprinting syndrome. Due to the intrinsic variability of MLID, the guidelines underscore the importance of involving experts from various fields to ensure a confident approach to diagnosis, counselling, and care. The authors advocate for global, collaborative efforts in both basic and translational research to tackle numerous crucial questions that currently lack answers, and suggest reconvening within the next 3-5 years to evaluate the research advancements and update this guidance as needed.
Subject(s)
DNA Methylation , Genomic Imprinting , Humans , Genomic Imprinting/genetics , DNA Methylation/genetics , Genetic Testing/methodsABSTRACT
Silver Russell syndrome (SRS) is a congenital disorder characterized by intrauterine growth retardation (IUGR), feeding difficulties and postnatal growth retardation. In a small number of cases, PLAG1 variants have been described (OMIM #618907). PLAG1 haploinsufficiency decreases Insulin-like growth factor 2 expression and produces a Silver Russell syndrome-like phenotype. Here, we describe the phenotype and molecular features of a 26 months girl with clinical features of SRS, and a de novo 2.1 Mb deletion encompassing PLAG1 is reported in association with clinical features suggestive of SRS.
Subject(s)
Silver-Russell Syndrome , DNA-Binding Proteins/genetics , Female , Humans , Phenotype , Silver-Russell Syndrome/diagnosis , Silver-Russell Syndrome/genetics , Transcription Factors/geneticsABSTRACT
OBJECTIVE: Genetic activation of the insulin signal-transducing kinase AKT2 causes syndromic hypoketotic hypoglycaemia without elevated insulin. Mosaic activating mutations in class 1A phospatidylinositol-3-kinase (PI3K), upstream from AKT2 in insulin signalling, are known to cause segmental overgrowth, but the metabolic consequences have not been systematically reported. We assess the metabolic phenotype of 22 patients with mosaic activating mutations affecting PI3K, thereby providing new insight into the metabolic function of this complex node in insulin signal transduction. METHODS: Three patients with megalencephaly, diffuse asymmetric overgrowth, hypoketotic, hypoinsulinaemic hypoglycaemia and no AKT2 mutation underwent further genetic, clinical and metabolic investigation. Signalling in dermal fibroblasts from one patient and efficacy of the mTOR inhibitor Sirolimus on pathway activation were examined. Finally, the metabolic profile of a cohort of 19 further patients with mosaic activating mutations in PI3K was assessed. RESULTS: In the first three patients, mosaic mutations in PIK3CA (p.Gly118Asp or p.Glu726Lys) or PIK3R2 (p.Gly373Arg) were found. In different tissue samples available from one patient, the PIK3CA p.Glu726Lys mutation was present at burdens from 24% to 42%, with the highest level in the liver. Dermal fibroblasts showed increased basal AKT phosphorylation which was potently suppressed by Sirolimus. Nineteen further patients with mosaic mutations in PIK3CA had neither clinical nor biochemical evidence of hypoglycaemia. CONCLUSIONS: Mosaic mutations activating class 1A PI3K cause severe non-ketotic hypoglycaemia in a subset of patients, with the metabolic phenotype presumably related to the extent of mosaicism within the liver. mTOR or PI3K inhibitors offer the prospect for future therapy.
Subject(s)
Class I Phosphatidylinositol 3-Kinases/genetics , Hypoglycemia/genetics , Insulin/genetics , Megalencephaly/genetics , Mosaicism , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins c-akt/genetics , Child, Preschool , Female , Humans , Hypoglycemia/diagnosis , Hypoglycemia/metabolism , Insulin/metabolism , Male , Megalencephaly/diagnosis , Megalencephaly/metabolism , Phosphatidylinositol 3-Kinases/metabolismABSTRACT
Beckwith-Wiedemann and Silver-Russell syndromes (BWS/SRS) are two imprinting disorders (IDs) associated with disturbances of the 11p15.5 chromosomal region. In BWS, epimutations and genomic alterations within 11p15.5 are observed in >70% of patients, whereas in SRS they are observed in about 60% of the cases. In addition, 10% of the SRS patients carry a maternal uniparental disomy of chromosome 7 11p15.5. There is an increasing demand for prenatal testing of these disorders owing to family history, indicative prenatal ultrasound findings or aberrations involving chromosomes 7 and 11. The complex molecular findings underlying these disorders are a challenge not only for laboratories offering these tests but also for geneticists counseling affected families. The scope of counseling must consider the range of detectable disturbances and their origin, the lack of precise quantitative knowledge concerning the inheritance and recurrence risks for the epigenetic abnormalities, which are hallmarks of these developmental disorders. In this paper, experts in the field of BWS and SRS, including members of the European network of congenital IDs (EUCID.net; www.imprinting-disorders.eu), put together their experience and work in the field of 11p15.5-associated IDs with a focus on prenatal testing. Altogether, prenatal tests of 160 fetuses (122 referred for BWS, 38 for SRS testing) from 5 centers were analyzed and reviewed. We summarize the current knowledge on BWS and SRS with respect to diagnostic testing, the consequences for prenatal genetic testing and counseling and our cumulative experience in dealing with these disorders.
Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Genetic Counseling/methods , Genetic Testing/methods , Prenatal Diagnosis/methods , Silver-Russell Syndrome/genetics , Beckwith-Wiedemann Syndrome/diagnosis , Genetic Counseling/standards , Genetic Testing/standards , Humans , Prenatal Diagnosis/standards , Silver-Russell Syndrome/diagnosisABSTRACT
OBJECTIVE: To investigate beta-cell function and the long-term health of four case subjects presenting with chromosome 6-associated transient neonatal diabetes (TND). RESEARCH DESIGN AND METHODS: Two unrelated case subjects presenting with paternal uniparental isodisomy of chromosome 6 (UPD6) and two siblings with a paternally inherited duplication of 6q24 were studied. Three case subjects presented with neonatal diabetes that recurred at 4-17 years, while diabetes was incidentally discovered in the other case subject at 14 years of age. beta-Cell function was investigated after diabetes relapse by means of an oral glucose tolerance test (OGTT), an intravenous glucose tolerance test (IVGTT), and glucagon tests. The quantitative insulin sensitivity check index (QUICKI) was calculated from fasting blood samples as an estimate of insulin sensitivity. RESULTS: beta-Cell function was investigated at diabetes relapse in two case subjects: the insulin response to both an OGTT and IVGTT was low, whereas the basal levels of C-peptide were normal. No evidence of insulin resistance was found. Residual beta-cell function was further explored by a glucagon test in all subjects at the age of 16-28 years and was found to be normal. Final height was within the normal percentiles, whereas one case, who had been poorly controlled since puberty, presented with diabetes-related microvascular complications. CONCLUSIONS: In patients with chromosome 6-associated TND, the beta-cell is preserved and able to secrete insulin through the stimulatory G protein pathway while exhibiting a specific defect of insulin secretion after glucose stimulation. This form of diabetes can be managed with insulin or diet, although new therapeutic agents (glucagon-like synthetic analogs) may prove useful in the future. Lack of treatment leads to long-lasting hyperglycemia without the risk of ketoacidosis but associated with microangiopathy in adult life.
Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 6 , Diabetes Mellitus/genetics , Glucagon/therapeutic use , Insulin/therapeutic use , Islets of Langerhans/physiopathology , Diabetes Mellitus/congenital , Female , Glucose Tolerance Test , Humans , Infant, Newborn , Insulin Resistance , Islets of Langerhans/drug effects , Male , Pedigree , Rare Diseases , Remission, Spontaneous , Risk Assessment , Sampling Studies , SiblingsABSTRACT
BACKGROUND: Neonatal diabetes has not been previously studied in Ukraine. We investigated the genetic etiology in patients with onset of diabetes during the ï¬rst 9 months of life. METHODS: We established a Pediatric Diabetes Register to identify patients diagnosed with diabetes before 9 months of age. Genetic testing was undertaken for 42 patients with permanent or transient diabetes diagnosed within the first 6 months of life (n=22) or permanent diabetes diagnosed between 6 and 9 months (n=20). RESULTS: We determined the genetic etiology in 23 of 42 (55%) patients; 86% of the patients diagnosed before 6 months and 20% diagnosed between 6 and 9 months. The incidence of neonatal diabetes in Ukraine was calculated to be 1 in 126,397 live births. CONCLUSIONS: Genetic testing for patients identified through the Ukrainian Pediatric Diabetes Register identified KCNJ11 and ABCC8 mutations as the most common cause (52%) of neonatal diabetes. Transfer to sulfonylureas improved glycemic control in all 11 patients.
Subject(s)
Diabetes Mellitus, Type 1/epidemiology , Infant, Newborn, Diseases/epidemiology , Mutation , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/genetics , Female , Genetic Testing , Humans , Hypoglycemic Agents/therapeutic use , Incidence , Infant , Infant, Newborn , Infant, Newborn, Diseases/drug therapy , Infant, Newborn, Diseases/genetics , Male , Phenotype , Potassium Channels, Inwardly Rectifying/genetics , Registries , Sulfonylurea Compounds/therapeutic use , Sulfonylurea Receptors/genetics , Ukraine/epidemiologyABSTRACT
The biological processes controlling human growth are diverse, complex and poorly understood. Genetic factors are important and human height has been shown to be a highly polygenic trait to which common and rare genetic variation contributes. Weaver syndrome is a human overgrowth condition characterised by tall stature, dysmorphic facial features, learning disability and variable additional features. We performed exome sequencing in four individuals with Weaver syndrome, identifying a mutation in the histone methyltransferase, EZH2, in each case. Sequencing of EZH2 in additional individuals with overgrowth identified a further 15 mutations. The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies. Our data establish EZH2 mutations as the cause of Weaver syndrome and provide further links between histone modifications and regulation of human growth.
Subject(s)
Abnormalities, Multiple/genetics , Congenital Hypothyroidism/genetics , Craniofacial Abnormalities/genetics , DNA-Binding Proteins/genetics , Germ-Line Mutation , Hand Deformities, Congenital/genetics , Transcription Factors/genetics , Amino Acid Sequence , Body Height , Enhancer of Zeste Homolog 2 Protein , Facies , Female , Growth Disorders/genetics , Histone Methyltransferases , Histone-Lysine N-Methyltransferase/genetics , Histones/genetics , Humans , Male , Polycomb Repressive Complex 2 , Sequence Analysis, DNAABSTRACT
Stickler syndrome is an autosomal dominant connective tissue disorder caused by mutations in different collagen genes. The aim of our study was to define more precisely the phenotype and genotype of Stickler syndrome type 1 by investigating a large series of patients with a heterozygous mutation in COL2A1. In 188 probands with the clinical diagnosis of Stickler syndrome, the COL2A1 gene was analyzed by either a mutation scanning technique or bidirectional fluorescent DNA sequencing. The effect of splice site alterations was investigated by analyzing mRNA. Multiplex ligation-dependent amplification analysis was used for the detection of intragenic deletions. We identified 77 different COL2A1 mutations in 100 affected individuals. Analysis of the splice site mutations showed unusual RNA isoforms, most of which contained a premature stop codon. Vitreous anomalies and retinal detachments were found more frequently in patients with a COL2A1 mutation compared with the mutation-negative group (P<0.01). Overall, 20 of 23 sporadic patients with a COL2A1 mutation had either a cleft palate or retinal detachment with vitreous anomalies. The presence of vitreous anomalies, retinal tears or detachments, cleft palate and a positive family history were shown to be good indicators for a COL2A1 defect. In conclusion, we confirm that Stickler syndrome type 1 is predominantly caused by loss-of-function mutations in the COL2A1 gene as >90% of the mutations were predicted to result in nonsense-mediated decay. On the basis of binary regression analysis, we developed a scoring system that may be useful when evaluating patients with Stickler syndrome.
Subject(s)
Arthritis/genetics , Collagen Type II/genetics , Connective Tissue Diseases/genetics , Hearing Loss, Sensorineural/genetics , Retinal Detachment/genetics , Abnormalities, Multiple/genetics , Cleft Palate/genetics , Collagen Type II/metabolism , Connective Tissue Diseases/metabolism , Craniofacial Abnormalities/genetics , DNA Mutational Analysis , Genetic Association Studies , Humans , Sequence Analysis, DNA , Sequence Analysis, RNAABSTRACT
Transient neonatal diabetes mellitus (TNDM) is diagnosed in the first 6 months of life, with remission in infancy or early childhood. For approximately 50% of patients, their diabetes will relapse in later life. The majority of cases result from anomalies of the imprinted region on chromosome 6q24, and 14 patients with ATP-sensitive K+ channel (K(ATP) channel) gene mutations have been reported. We determined the 6q24 status in 97 patients with TNDM. In patients in whom no abnormality was identified, the KCNJ11 gene and/or ABCC8 gene, which encode the Kir6.2 and SUR1 subunits of the pancreatic beta-cell K(ATP) channel, were sequenced. K(ATP) channel mutations were found in 25 of 97 (26%) TNDM probands (12 KCNJ11 and 13 ABCC8), while 69 of 97 (71%) had chromosome 6q24 abnormalities. The phenotype associated with KCNJ11 and ABCC8 mutations was similar but markedly different from 6q24 patients who had a lower birth weight and who were diagnosed and remitted earlier (all P < 0.001). K(ATP) channel mutations were identified in 26 additional family members, 17 of whom had diabetes. Of 42 diabetic patients, 91% diagnosed before 6 months remitted, but those diagnosed after 6 months had permanent diabetes (P < 0.0001). K(ATP) channel mutations account for 89% of patients with non-6q24 TNDM and result in a discrete clinical subtype that includes biphasic diabetes that can be treated with sulfonylureas. Remitting neonatal diabetes was observed in two of three mutation carriers, and permanent diabetes occurred after 6 months of age in subjects without an initial diagnosis of neonatal diabetes.
Subject(s)
ATP-Binding Cassette Transporters/genetics , Diabetes Mellitus/genetics , Potassium Channels, Inwardly Rectifying/genetics , Potassium Channels/genetics , Receptors, Drug/genetics , Adenosine Triphosphate , Child, Preschool , Humans , Infant , Infant, Newborn , Mutation , Pedigree , Sulfonylurea ReceptorsABSTRACT
Treacher Collins syndrome (TCS) is an autosomal dominant disorder of facial development, which results from mutations in TCOF1. TCS comprises conductive hearing loss, hypoplasia of the mandible and maxilla, downward sloping palpebral fissures and cleft palate. Although, there is usually a reasonable degree of bilateral symmetry, a high degree of both inter- and intrafamilial variability is characteristic of TCS. The wide variation in the clinical presentation of different patients, together with the fact that more than 60% of cases arise de novo, can complicate the diagnosis of mild cases and genetic counselling. In the current study, we describe how molecular techniques have been used to facilitate pre- and postnatal disease diagnoses in 13 TCS families.
Subject(s)
Mandibulofacial Dysostosis/diagnosis , Mutation , Nuclear Proteins/genetics , Phosphoproteins/genetics , Female , Humans , Male , Mandibulofacial Dysostosis/genetics , Pedigree , Prenatal DiagnosisABSTRACT
A mild, catalytic dehydrocoupling route to aminoboranes and borazine derivatives from either primary or secondary amine-borane adducts has been developed using late transition metal complexes as precatalysts. The adduct Me(2)NH.BH(3) thermally eliminates hydrogen at 130 degrees C in the condensed phase to afford [Me(2)N-BH(2)](2) (1). Evidence for an intermolecular process, rather than an intramolecular reaction to form Me(2)N=BH(2) as an intermediate, was forthcoming from "hot tube" experiments where no appreciable dehydrocoupling of gaseous Me(2)NH.BH(3) was detected in the range 150-450 degrees C. The dehydrocoupling of Me(2)NH.BH(3) was found to be catalyzed by 0.5 mol % [Rh(1,5-cod)(mu-Cl)](2) in solution at 25 degrees C to give 1 quantitatively after ca. 8 h. The rate of dehydrocoupling was significantly enhanced if the temperature was raised or if the catalyst loading was increased. The catalytic activity of various other transition metal complexes (Ir, Ru, Pd) for the dehydrocoupling of Me(2)NH.BH(3) was also demonstrated. This new catalytic method was extended to other secondary adducts RR'NH.BH(3) which afforded the dimeric species [(1,4-C(4)H(8))N-BH(2)](2) (2) and [PhCH(2)(Me)N-BH(2)](2) (3) or the monomeric aminoborane (i)Pr(2)N=BH(2) (4) under mild conditions. A new synthetic approach to the linear compounds R(2)NH-BH(2)-NR(2)-BH(3) (5: R = Me; 6: R = 1,4-C(4)H(8)) was developed and subsequent catalytic dehydrocoupling of these species yielded the cyclics 1 and 2. The species 5 and 6 are postulated to be intermediates in the formation of 1 and 2 directly from the catalytic dehydrocoupling of the adducts R(2)NH.BH(3). The catalytic dehydrocoupling of NH(3).BH(3), MeNH(2).BH(3), and PhNH(2).BH(3) at 45 degrees C to give the borazine derivatives [RN-BH](3) (10: R = H; 11: R = Me; 12: R = Ph) was demonstrated. TEM analysis of the contents of the reaction solution for the [Rh(1,5-cod)(mu-Cl)](2) catalyzed dehydrocoupling of Me(2)NH.BH(3) together with Hg poisoning experiments suggested a heterogeneous catalytic process involving Rh(0) colloids.